Trans-sodium crocetinate

Drug Profile

Trans-sodium crocetinate

Alternative Names: Sodium crocetinate; Transcrocetinate sodium; TSC

Latest Information Update: 15 Jun 2016

Price : $50

At a glance

  • Originator University of Virginia
  • Developer Diffusion Pharmaceuticals
  • Class Carotenoids; Radiation-sensitising agents; Small molecules; Vascular disorder therapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain metastases; Glioblastoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Glioblastoma
  • Preclinical Brain metastases; Pancreatic cancer
  • No development reported Peripheral arterial disorders

Most Recent Events

  • 08 Jun 2016 Diffusion Pharmaceuticals receives patent allowance for use of trans-sodium crocetinate in five hypoxia-related conditions in USA
  • 15 Mar 2016 Preclinical trials in Brain metastases in USA (IV) before March 2016
  • 15 Mar 2016 Preclinical trials in Pancreatic cancer in USA (IV) before March 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top